Bernstein Remains a Hold on AbbVie Inc. (ABBV)

AbbVie Inc. (NYSE:ABBV) is one of the best medical stocks to buy now. In a report released on September 25, Courtney Breen from Bernstein maintained a Hold rating on AbbVie Inc. (NYSE:ABBV) without assigning a price target.

AbbVie Inc. (NYSE:ABBV) reported in its fiscal Q2 2025 earnings that the diluted EPS for the quarter reached $0.52 on a GAAP basis, reflecting a 32.5% drop.

Adjusted diluted EPS, however, rose 12.1% to $2.97. Management reported that the results included an “unfavorable impact of $0.42 per share related to acquired IPR&D and milestones expense”.

Furthermore, net revenue for fiscal Q2 2025 rose 6.6% on a reported basis to $15.423 billion.

AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.

While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.